About
Exelixis Inc (NASDAQ:EXEL) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Feb 24 2026
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
Feb 10 2026
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Feb 2 2026
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Jan 27 2026
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Financials
Revenue
$2.32 B
Market Cap
$11.76 B
P/E Ratio
15.78
EPS
2.78
Translate